



Q4 and Full Year 2020 Financial Results

February 4, 2021



Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the risks and uncertainties related to the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the risks and uncertainties related to the development, manufacturing and distribution of Veklury (remdesivir) as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury revenues and the risk that Gilead may be unable to recoup the expenses incurred to date and future expenses related to the development and production of Veklury, and Gilead may be unable to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2021 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in research and development expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions laid out in its corporate strategy; Gilead's ability to achieve any of its key corporate objectives in 2021; Gilead's ability to accelerate or sustain revenues for its antiviral and other programs; Gilead's ability to achieve any of its 2021 capital allocation priorities; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including those of or with Arcus Biosciences, Inc., Immunomedics, Inc., Pionyr Immunotherapeutics, Inc., Tizona Therapeutics, Inc. and, upon closing, MYR GmbH; Gilead's ability to complete the MYR GmbH acquisition in a timely manner or at all; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated time frames; the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Tecartus, Trodelvy and Yescarta; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including cilofexor, fircostat, filgotinib, lenacapavir, magrolimab and remdesivir, or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, including U.S. Food and Drug Administration approval of Trodelvy, and European Medicines Agency approval of filgotinib, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products; the risk that efforts to control prescription drug prices could have a material adverse effect on Gilead's business; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter and the year ended December 31, 2020 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

This presentation includes U.S. GAAP and non-GAAP financial measures, a complete reconciliation between these two measures is available on the Company's website at www.gilead.com within the investor section. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under U.S. GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPLUSA®, EVIPLERA®, GENVOYA®, HARVON®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TECARTUS™, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This presentation also includes trademarks, service marks and trade names of other companies.



COVID-19 Insight Statements

We have provided these insights based on management's current expectations, estimates and judgments, which are based on information available as of the date of this presentation and certain assumptions that it believes to be reasonable under the circumstances, but the risks and uncertainties related to the COVID-19 pandemic and related public health measures could cause actual results to differ materially. The extent to which the COVID-19 pandemic impacts our business, financial condition and results of operations will depend on future developments, which are uncertain and cannot be predicted with confidence, including the duration and scope of the outbreak, any potential future waves of the pandemic, new information which may emerge concerning the severity of COVID-19 and the ongoing or future actions to contain it or treat its impact, among others. The ongoing COVID-19 pandemic may also affect our operating and financial results in a manner that is not presently known to us or that we currently do not consider to present significant risks to our operations.



Contents

Business Update

4-8

Financial Performance

9-20

Commercial Performance

21-31

Research & Development Update

32-42

Appendix

43-50



Business Update



Earnings Call Highlights

Overall Financial Performance Exceeded Expectations

- **Total product sales** of \$7.3B in Q4 and \$24.4B in FY 2020
 - Q4 sales increased 26% YoY primarily due to \$1.9B of Veklury sales
 - FY product sales excluding Veklury declined 3% YoY primarily due to Atripla and Truvada LOEs and impact of COVID-19 on our HIV and HCV franchises
 - 2020 HIV sales \$16.9B, +3% YoY growth despite US LOE and COVID-19 impact
 - Biktarvy FY sales increased 53% YoY to \$7.3B
- **Non-GAAP diluted EPS** of \$2.19 in Q4 (+4% QoQ) and \$7.09 for FY 2020 (+16% YoY)

Significantly Expanded and Strengthened Clinical Pipeline

- **Completed 18 tailored transactions in 2020**, providing optionality across TAs
- **Increased pipeline size by >50% overall** with notable opt-in opportunities
- **Creative deal structures** allowing opt-in after proof-of-concept data

On Clear Path to Near and Long-term Growth

- **Advancing key therapies in oncology**
 - Trodelvy is a foundational asset with potential across multiple solid tumors
- **Continued leadership in antivirals**
 - Biktarvy expected to remain #1 prescribed regimen in HIV treatment in the near and mid-term
 - Lenacapavir could be a best-in-class long-acting agent for HIV treatment and prevention
 - Additional growth in HBV and expected entry into HDV
- **Strong focus on prioritization and execution across the portfolio**



2020: Building for Growth

2020 Strategy Execution Highlights



Completed **significant BD activity** to enhance commercial portfolio and clinical pipeline



Increased **pipeline size by 50% overall**¹ with notable opt-in opportunities



Re-prioritized programs and created **new governance for the portfolio**



Five new product approvals², including COVID-19 treatment, Veklury



Recruited key talent (research, clinical development, data science, commercial strategy) with **significant build in oncology**

2020 Select Milestones

Select BD:



MYR GmbH²

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Product Approvals³:



¹ Measured by asset-indication projects, net change today vs. January 2020. ² Includes Hepcludex. Agreement to acquire MYR has been announced but not yet closed. Closing of transaction subject to regulatory clearances and other conditions. ³ Details regarding the state of product approvals provided in subsequent slides.



Clear Path to Near and Long-Term Growth

Excluding Veklury (remdesivir)

**Deliver on Opportunities
in New Therapeutic Areas**




**Continue Leadership
in Antivirals**



**Prioritize and Execute
Across Portfolio**



*Illustrative Growth
(Excluding Veklury)*



Key Areas of Focus for Gilead in 2021

Antiviral Leadership

Continue growth of Biktarvy and maintain leadership as #1 treatment for HIV

Develop lenacapavir as a foundation for long-acting HIV therapies

- FDA submission in heavily treatment experienced population
- Identify long-acting molecule(s) for combination potential

Expand viral hepatitis business

- Grow **Vemlidy** sales in US and Asia as the leading treatment for HBV
- Submit **Hepcludex** BLA to the US FDA as a novel, first-in-class treatment for HDV¹

Realize full potential of Veklury as part of ongoing fight against COVID-19

Oncology Expansion

Establish Trodelvy as a key growth driver and pursue broad potential as cornerstone therapy

- **Trodelvy** US full approval for mTNBC
- **Trodelvy** US accelerated approval for mUC
- **Trodelvy** Ph3 readout in HR+/HER2- mBC

Advance additional key oncology therapies

- **Yescarta** Ph3 ZUMA-7 readout in 2L DLBCL
- **Magrolimab** Ph1b readout in 1L MDS
- **Opt-in opportunities** from partnerships

Enterprise Focus

Recruit and develop key talent and further expand capabilities

Increase **focus on prioritization** to ensure appropriate resource investment

Address **racial inequity** through internal and external efforts

Continue to advance **ESG program** and targets in line with our strategy



Financial Performance



Q4 & FY 2020

Financial Highlights

- **Robust product sales growth driven by Biktarvy and Veklury**
 - Q4 sequential growth of 13% and full year growth of 10%
 - Q4 revenue excluding Veklury decreased 4% sequentially primarily due to the Atripla and Truvada LOEs
 - Full year HIV revenue grew 3% driven by strong Biktarvy and Descovy uptake despite LOEs and impact of the COVID-19 pandemic
 - Full year Biktarvy revenue grew by \$2.5 billion and remains the #1 prescribed regimen in the U.S.
- **Operating expenses driven by investments in our business to drive growth and increased corporate grants to support racial equity and help our non-profit grantees weather the pandemic**
 - Q4 sequential increase in R&D driven by investments in magrolimab and Trodelvy, \$190 million related to the Galapagos amendment, and ~\$70 million in milestones to Pionyr
 - Q4 sequential growth in SG&A driven by timing of Biktarvy marketing spend, Veklury and Trodelvy commercialization efforts, and increased corporate grants
 - Full year R&D growth largely driven by at risk investments in Veklury, Galapagos amendment, and Pionyr milestones, partially offset by lower spend on inflammation and postponement of certain clinical trials due to the pandemic
 - Full year SG&A increase largely driven by commercial spend on Biktarvy, Veklury, and Trodelvy, increased corporate grants, remdesivir donations, and a \$97 million legal settlement
- **Non-GAAP diluted EPS increased 99% YoY for the quarter and 16% for the full year**
 - Growth for the quarter and year driven by Biktarvy and Veklury sales, improved gross margin and a lower tax rate partially offset by COVID-19, LOEs, and higher operating expenses
- **\$5 billion total shareholder return in 2020, representing ~67% of Free Cash Flow**



Financial Highlights: Q4 2020

in millions, except percentages and per share amounts

	Q4 2019	Q3 2020	Q4 2020	YoY Change	QoQ Change
HIV ¹	4,577	4,547	4,257	(7%)	(6%)
Other Products ²	1,219	1,073	1,133	(7%)	6%
Product Sales excluding Veklury	\$5,796	\$5,620	\$5,390	(7%)	(4%)
Veklury	-	873	1,938	NM	122%
Product Sales	\$5,796	\$6,493	\$7,328	26%	13%
COGS	1,417	875	918	(35%)	5%
Product Gross Margin	76%	87%	88%		
R&D	1,103	1,155	1,512	37%	31%
SG&A	1,204	1,095	1,499	25%	37%
Non-GAAP Costs and Expenses³	\$3,724	\$3,125	\$3,929	6%	26%
Non-GAAP Operating Income	\$2,155	\$3,452	\$3,492	62%	1%
Operating Margin	37%	53%	47%		
Effective Tax Rate	32%	18%	16%		
Non-GAAP Net Income³	\$1,400	\$2,657	\$2,762	97%	4%
Non-GAAP Diluted EPS ³	\$1.10	\$2.11	\$2.19	99%	4%
Shares used in per share calculation-diluted	1,273	1,261	1,259	(1%)	NM

¹ HIV includes Atripla, Biktarvy, Complera/Eviplera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, revenue share Symtuza, Truvada, and Tybost. Revenue share Symtuza represents Gilead's revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen. ² Other products include AmBisome, Cayston, Hepsera, Jyseleca, Letairis, Ranexa, Tecartus, Trodelvy, Vemlidy, Viread, Vosevi, Yescarta, Zydelig, Harvoni and Eplusa as well as Harvoni authorized generic and Eplusa authorized generic sold by Gilead's subsidiary, Asegua Therapeutics, LLC. ³ Beginning in the first quarter 2020, Gilead no longer regularly excludes share-based compensation expense from its IPR&D expenses, and other items that are considered unusual or not representative of underlying trends of Gilead's business, fair value adjustments of equity non-GAAP financial information. To conform to this change, the prior period non-GAAP financial information has been recast to include share-based compensation expense. Non-GAAP financial information excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges in Cost of goods sold, acquired IPR&D expenses, and other items that are considered unusual or not representative of underlying trends of Gilead's business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. NM - Not Meaningful.



Financial Highlights: Full Year

in millions, except percentages and per share amounts


	2019	2020	YoY Change
HIV ¹	\$16,438	\$16,938	3%
Other Products ²	5,681	4,606	(19%)
Product Sales excluding Veklury	\$22,119	\$21,544	(3%)
Veklury	-	2,811	NM
Product Sales	\$22,119	\$24,355	10%
COGS	3,587	3,294	(8%)
Product Gross Margin	84%	87%	
R&D	4,059	4,857	20%
SG&A	4,375	4,834	10%
Non-GAAP Costs and Expenses³	\$12,021	\$12,985	8%
Non-GAAP Operating Income	\$10,428	\$11,704	12%
Operating Margin	47%	47%	
Effective Tax Rate	22%	19%	
Non-GAAP Net Income³	\$7,828	\$8,959	14%
Non-GAAP Diluted EPS ³	\$6.13	\$7.09	16%
Shares used in per share calculation-diluted	1,277	1,263	(1%)

¹ HIV includes Atripla, Biktarvy, Complera/Eviplera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, revenue share Symtuza, Truvada, and Tybost. Revenue share Symtuza represents Gilead's revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen. ² Other products include AmBisome, Cayston, Hepsera, Jyseleca, Letairis, Ranexa, Tecartus, Trodelvy, Vemlidy, Viread, Vosevi, Yescarta, Zydelyg, Harvoni and Eplclusa as well as Harvoni authorized generic and Eplclusa authorized generic sold by Gilead's subsidiary, Asegua Therapeutics, LLC. ³ Beginning in the first quarter 2020, Gilead no longer regularly excludes share-based compensation expense from its non-GAAP financial information. To conform to this change, the prior period non-GAAP financial information has been recast to include share-based compensation expense. Non-GAAP financial information excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges in Cost of goods sold, acquired IPR&D expenses, and other items that are considered unusual or not representative of underlying trends of Gilead's business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. NM Not Meaningful.



Net Product Sales

in millions



Q4'20 up 13% from Q3'20

- Growth driven by higher Veklury sales
- Excluding Veklury, revenue declined 4% driven by the loss of exclusivity on Atripla and Truvada in the U.S., partially offset by strong Biktarvy performance


Q4'20 up 26% from Q4'19

- Growth driven by higher Veklury sales
- Excluding Veklury, revenue declined 7% driven by the LOEs and the impact of COVID-19 on our HIV and HCV franchises, partially offset by robust Biktarvy and Descovy uptake



Non-GAAP R&D Expenses

in millions



Q4'20 up 31% from Q3'20

- Increase driven by the Galapagos amendment of \$190 million and Pionyr collaboration milestones of ~\$70 million as well as pipeline investments in magrolimab and Trodelvy


Q4'20 up 37% from Q4'19

- Increase driven by Galapagos and Pionyr as well as pipeline investments in magrolimab, Trodelvy, and remdesivir



Non-GAAP SG&A Expenses

in millions



Q4'20 up 37% from Q3'20


- Primarily driven by increased corporate grants to support racial equity and help our non-profit grantees weather the pandemic, investments in Veklury, Trodelvy, and cell therapy, and higher marketing program costs reflecting typical seasonality

Q4'20 up 25% from Q4'19

- Primarily driven by increased corporate grants, investments in Veklury, Trodelvy, and China expansion



Non-GAAP Diluted EPS



Q4'20 increased from Q3'20

- Increase due to higher Biktarvy and Veklury sales
- Partially offset by the impact of LOEs and increased operating expenses including Galapagos amendment, Pionyr collaboration milestones, and corporate grants

Q4'20 increased from Q4'19

- Increase due to higher Biktarvy and Veklury sales, improved gross margin due to \$500 million inventory write-down charge in Q4 2019, and lower tax rate due to tax credits and settlements with tax authorities
- Partially offset by the impact of COVID-19, LOEs and increased operating expenses



2020 Shareholder Return

	Dividend Dollar Amount (in millions)	Dividend per Share	Repurchase Dollar Amount ¹ (in millions)	Shares	Average Purchase Price	Total Shareholder Return (in millions)
Q1 '20	\$875	\$0.68	\$1,328	18,749,098	\$70.82	\$2,203
Q2 '20	\$855	\$0.68	\$53	700,100	\$76.39	\$908
Q3 '20	\$861	\$0.68	\$202	2,960,548	\$68.13	\$1,063
Q4 '20	\$858	\$0.68	\$0	0	\$0.00	\$858
YTD '20	\$3,449	\$2.72	\$1,583	22,409,746	\$70.64	\$5,032

2020 total shareholder return was ~67% of Free Cash Flow²

Dividend

- Declared a quarterly dividend increase of 4.4% from \$0.68 to \$0.71 per share, beginning in the first quarter of 2021
- The Q1'21 quarterly dividend is payable on March 30, 2021 to stockholders of record as of the close of business on March 15, 2021

Repurchase

- A \$12.0 billion share repurchase program was authorized in January 2016, which we began in Q2'16. Under this program, we have purchased ~137.5 million shares at an average price of \$74.09 for a total of ~\$10.2 billion as of December 31, 2020
- As of December 31, 2020, there is ~\$6.8 billion authorization remaining under current share repurchase programs (~\$1.8 billion under January 2016 program and \$5.0 billion under January 2020 program)




Full Year 2021 Guidance

in millions, except percentages and per share amounts	Provided on February 4, 2021	Comments
Product Sales x-Veklury	\$21,700 – \$22,100	1-3% growth despite Atripla and Truvada LOEs in the U.S.
Veklury Sales	\$2,000 – 3,000	Wide range driven by uncertainty related to the pandemic
Total Product Sales	\$23,700 – \$25,100	
Non-GAAP		
Product Gross Margin	87% – 88%	Consistent with historic performance
R&D Expense	Flat to low single-digit % decline	Reduced investments in filgotinib and remdesivir largely offset by increased investments in magrolimab, Trodelvy and other pipeline programs
SG&A Expense	Flat to low single-digit % decline	Includes oncology build-out and funding of time-limited corporate initiatives related to IT infrastructure and data analytics
Operating Income	\$11,500 – \$12,900	Leverage efficient operating model to drive growth despite LOEs
Effective Tax Rate	~21%	
Diluted EPS	\$6.75 – \$7.45	Reflects higher taxes and lower other income and expenses
GAAP Diluted EPS	\$5.25 – \$5.95	

Product sales guidance assumes recovery towards pre-COVID-19 baseline starting in Q2'21. This financial guidance reflects the impact of recent corporate development transactions, including our planned acquisition of MYR Pharmaceuticals, as well as funding for ordinary course partnering activities in 2021 but excludes the effects of any potential future extraordinary acquisitions, collaborations and investments, the exercise of significant opt-ins or options related to collaboration programs where Gilead has such rights with its collaboration partners, and any other transactions or items that have not yet been identified or quantified. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements on page 2.



2021 Product Sales Guidance excluding Veklury



2021 Capital Allocation Priorities

Continue to invest in our business and R&D pipeline while managing expenses

Grow our dividend and pay down at least \$4B of debt

Repurchase shares to offset dilution and opportunistically reduce share count



Commercial Performance



Commercial Revenue Highlights: Q4 2020


in millions, except percentages	Q1 2020	Q2 2020	Q3 2020	Q4 2020	QoQ Change
HIV ¹	\$4,134	\$4,000	\$4,547	\$4,257	(6%)
HCV	729	448	464	423	(9%)
HBV ²	186	219	211	244	16%
Cell Therapy ³	140	157	147	163	11%
Trodelvy	-	-	-	49*	NM
Veklury	-	-	873	1,938	122%
Other Products ⁴	278	243	251	254	1%
Product Sales	\$5,467	\$5,067	\$6,493	\$7,328	13%
United States	\$3,989	\$3,770	\$5,076	\$5,306	5%
Europe	927	724	877	1,366	56%
Other International	551	573	540	656	21%
Product Sales	\$5,467	\$5,067	\$6,493	\$7,328	13%

¹ HIV includes Atripla, Biktarvy, Complera/Eviplera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, revenue share Symtuza, Truvada, and Tybost. Revenue share Symtuza represents Gilead's revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen. ²HBV includes Hepsera, Vemlidy and Viread. ³Cell Therapy includes Yescarta and Tecartus. ⁴ Other products include AmBisome, Cayston, Jyseleca, Letairis, Ranexa and Zydelig. *Trodelvy sales for the fourth quarter and full year 2020, including the period prior to the completion of Gilead's acquisition of Immunomedics, were \$64 million and \$137 million. NM - Not Meaningful.



HIV Franchise Product Sales

in millions



Q4'20 down 6% from Q3'20

- Decrease primarily driven by lower sales volume of Atripla and Truvada in connection with the U.S. loss of exclusivity in Q4'20

Q4'20 down 7% from Q4'19

- Decrease primarily driven by lower sales volume of Atripla and Truvada in connection with the loss of exclusivity in Q4'20
- Partially offset by the continued uptake of Biktarvy and growth of Descovy for PrEP

Expect a continued decline in Truvada sales in Q1'21 and beyond as multiple generics expected to enter the market starting Q2'21




COVID-19 Insight: Dynamic HIV patient volumes (naive and switches) recovered from their trough levels in Q2'20 however the recent COVID-19 surge in Q4'20 has dampened recovery.



HIV Franchise Biktarvy is the Standard of Care in HIV

Total US HIV Treatment Regimen Volume¹



#1

Prescribed Regimen in US and Other Regions²

53%

YoY Revenue Growth 2020 vs. 2019

~1 in 2

U.S. patients initiating on Biktarvy

US Market Exclusivity Through

2033


¹ IQVIA National Prescription Audit (NPA) Monthly; Other drugs not labeled in this graph include: Genvoya, Triumeq, Descovy, Symtuza, Juluca and Dovato ² Biktarvy #1 prescribed HIV regimen in U.S. in Q4 '20, source Ipsos. US Source: Ipsos Healthcare U.S. HIV Monitor & Scope Study Q4 '20. Biktarvy #1 prescribed HIV regimen in France, Germany, Italy and Spain in Q4 '20, source Ipsos HIV Mini Monitor Q4'20



Oncology

Trodelvy Launch Progressing Well

Trodelvy US Product Sales



- Total Q4'20 Net Revenue of \$64M and FY20 Net Revenue of \$137M
 - Gilead Q4'20 Net Revenue: \$49M (portion of sales post-deal close on Oct 23rd)
- Trodelvy established as #1 therapy in 3L mTNBC within 8 months of launch²



Potential additional growth drivers in 2021:

- Publication of full ASCENT Ph3 study and NCCN category update expected in H1'21
- Full FDA approval for TNBC anticipated in H1'21
- Accelerated FDA approval for mUC anticipated in H1'21
- EMA filing for TNBC expected in H1'21



Trodelvy Has Broad Expansion Opportunities Across Multiple Tumor Types




Broad Applicability

Trodelvy targets Trop-2 which is expressed in multiple cancers suggesting broad applicability




Combination Potential

Opportunity to combine with checkpoint inhibitors, targeted agents, and/or chemotherapy



HCV Franchise Product Sales

in millions



Q4'20 down 9% from Q3'20

- Decrease primarily driven by the timing of purchases in other international markets

Q4'20 down 33% from Q4'19

- Decrease primarily driven by lower patient starts in the U.S. and Europe due to COVID-19
- Maintained strong U.S. market share ~58%




COVID-19 Insight: Patient starts recovered from their trough levels in Q2'20, however the latest surge in Q4'20 has dampened recovery (patient starts down ~30% in U.S. and down ~40% in EU5 vs. Q4'19).



Viral Hepatitis

Progress in Viral Hepatitis Further Strengthens Core Antiviral Business


Expected HBV Sales of \$1B+ by 2022¹



Continuing to lead in **HBV Cure**:
Ph2 combination studies to initiate this year

Novel HDV Therapy

HEPCLUDEX is a first-in-class and potentially best-in-class treatment for HDV²




Conditional approval in EU; US BLA submission expected in 2H 2021; more approvals, including in Asia, expected in 2023+



Viral Hepatitis Delta Virus Overview

HDV Prevalence



>12M

patients chronically infected
with HDV globally^{1,2}

~230K

Est. infected
in U.S. and EU²

<20%

Est. to be diagnosed
in U.S. and EU^{1,2}

Recently, increased screening and awareness has resulted in increased identification of patients worldwide but **HDV continues to remain under-diagnosed**^{1,2}

HDV Increases Risk of Poor Outcomes¹

(Compared to HBV mono-infected patients)

3.9x increased risk of cirrhosis

2.0x increased risk of HCC


2.1x increased risk for death

HDV occurs as a co-infection in HBV patients and is the most severe form of viral hepatitis¹

HDV is a progressive disease with ~80% patients developing cirrhosis in 5-10 years and high rates of HCC and hepatic decompensation^{1,3-5}

Cell Therapy Franchise Tecartus Launch Renewing Growth to Cell Therapy Franchise

Cell Therapy Product Sales



Total Cell Therapy Product Sales: Q4'20: \$163M, FY20: \$607M

Yescarta:

- Net Sales: Q4'20: \$129M (+6% YoY), FY20: \$563M (+23% YoY)
 - H2'20 US revenues impacted by COVID-19 pandemic with slowing community referrals and ICU bed constraints at treatment centers
- Enhanced market access and a **network of 210+ ATCs** for patients
- Market leading 4 year efficacy data presented at ASH Dec'20

Tecartus²:

- Net sales Q4'20: \$34M, FY20: \$44M
- **First and only cell therapy** to gain FDA approval in **MCL**
- **Rapid U.S. uptake** for r/r patients with high unmet medical need

Potential additional growth drivers in 2021:

- US Submission for **2L DLBCL on track for 2021** (ZUMA-7)
- US **iNHL sBLA submission** with potential approval in 2021 (ZUMA-5)
- Tecartus **MCL EU approval** and potential US approval** for **adult ALL in 2021**



Veklury Progresses in Highly Unpredictable Environment



~1 in 2

Patients hospitalized in the US treated with Veklury¹

~1M

US Patients treated with Veklury¹

40+

Interventional or observational studies²

Only FDA approved antiviral for COVID-19³

Multiple dynamic factors impacting uptake

Hospital shipments of Veklury increased in Q4'20 driven by surge in COVID-19 cases and hospitalizations

Veklury global sales of \$1.9 billion in Q4'20

Revenue being reinvested into future innovation through additional pipeline development

¹ Patients treated and utilization estimates based on volume donated and shipped for distribution within the US, assumed average treatment course of 6.25 vials/patient); ² Interventional or observational studies registered on clinicaltrials.gov either completed, underway or planned evaluating the use of remdesivir alone; as background therapy; or in combination with other agents in patients with COVID-19. ³ EMA granted conditional approval to VEKLURY.



Research & Development Update




Overview of Clinical Pipeline Today

52 Clinical stage programs^{1, 2}
18 through BD since Jan '19

17 NDA/BLA/MAA filings,
P3 and Registrational P2 trials

14 Clinical stage NMEs via
in-licensing, and
acquisitions accounting
for 24 programs

7 Breakthrough Therapy
Designations



¹ Including in-licensed or acquired programs currently between phase 1 and NDA/BLA/MAA approval. ² Includes Hepcludex. Agreement to acquire MYR has been announced but not yet closed. Closing of transaction subject to regulatory clearances and other conditions.



Oncology

Accelerating Oncology Portfolio and Expertise Buildout



Magrolimab (CD47)
Anti SIRP-a
Anti c-KIT



JTX-1811 (CCR8)



PY314 (TREM2)
PY159 (TREM1)

Immunomedics

TRODELVY™
sacituzumab govitecan-hziy
180 mg for injection

First-in-class antibody-drug conjugate for triple-negative breast cancer¹



Zimberelimab (PD-1), Domvanalimab (TIGIT)
Etrumadenant (A2a/A2bR), AB680 (CD73)
+ others



TTX-080 (HLA-G)



Protein Degradation
Discovery Collaboration



AGEN2373 (CD137)



Novel AML Targets
for Cell Therapy



BCMA Antibodies
for Cell Therapy



Discovery Collaboration
for Cell Therapy



IO Discovery
Collaboration



IO Discovery
Collaboration

Select Internal Assets:	PD-L1 small molecule (GS-4224)	MCL1 inhibitor (GS-9716)	FLT3R agonist (GS-3583)	MAGE A3/A6 (KTE-718)	CLL-1 (KTE-222)	HPV-16 E7 (KTE-439)
-------------------------	--------------------------------	--------------------------	-------------------------	----------------------	-----------------	---------------------

Building internal pipeline with 13 tailored transactions to access external innovation in last 2 years




Trodelvy Brings Transformational Benefit to 3L+ mTNBC; Filed for Accelerated Approval in 3L mUC



TRODELVY™
sacituzumab govitecan-hzly

- **is a foundational therapy** offering **transformational benefits** in 3L+ mTNBC
- sBLAs filed with FDA for full approval in 3L mTNBC and accelerated approval in mUC 3L
- EMA MAA filing in 3L+ mTNBC expected Q1'21
- **PFS data readout in 2H 2021** for TROPiCS-02 Phase 3 trial in 3L+ HR+/HER2- mBC (OS data in 2023)



Oncology Trodelvy Studies Demonstrate Expansion Opportunity

Trial	Indication	Phase 1	Phase 2	Phase 3	Filed	Approved
IMMU-132-01	mTNBC (3L+)	[Progress bar spanning Phase 1, 2, 3, Filed, and Approved]				
ASCENT	mTNBC (3L)	[Progress bar spanning Phase 1, 2, 3, and Filed, with text "sBLA filed for full approval" in Phase 3]				
TROPHY U-01	Urothelial (3L+)	[Progress bar spanning Phase 1, 2, 3, and Filed, with text "sBLA filed for accelerated approval" in Phase 3]				
TROPiCS-02	HR+/HER2- mBC (3L+)	[Progress bar spanning Phase 1, 2, and 3]				
TROPiCS-03	Basket (mNSCLC / H&N / endometrial)	[Progress bar spanning Phase 1 and 2]				
MORPHEUS	mTNBC (1L) / mUC / mNSCLC (+Tecentriq)	[Progress bar spanning Phase 1 and 2, with text "Phase 1b/2" in Phase 2]				
SEASTAR	mTNBC / mUC / Ovarian (2L+) (+ Rubraca)	[Progress bar spanning Phase 1 and 2, with text "Phase 1b/2" in Phase 2]				



Morpheus and Seastar trials are partner sponsored studies with Genentech and Clovis Oncology, respectively. Clinical pipeline shown does not include investigator sponsored trials (ISTs). These ISTs include collaborations 1) with German Breast Group to evaluate Trodelvy in HER2- breast cancer in the post-neoadjuvant setting, 2) with Dana Farber Cancer Institute and Merck to evaluate Trodelvy + Keytruda in advanced breast cancers, 3) with Massachusetts General Hospital to evaluate Trodelvy in TNBC in the neoadjuvant setting and Trodelvy + Talzena in 2L mTNBC, and 4) has further collaborations with Yale, U of Wisconsin and UT Health at San Antonio to evaluate Trodelvy in other solid tumor types.



Oncology

Magrolimab Update

Updated magrolimab + azacitidine data in frontline AML patients¹ presented at ASH 2020

- Demonstrated continued robust efficacy in both all-comers and TP53 mutant patients
- ORR of 63% with 42% CR rate in all-comer AML patients and similar responses in TP53 mutant

Phase 1b data read out expected in 2H 2021 for magrolimab + azacitidine in MDS

- Possibility for filing by year end 2021 in frontline higher risk MDS based on response rate and durability

Enrollment progressing well on the ENHANCE randomized Phase 3 study in MDS

Multiple Phase 1b/2 and 2 studies to evaluate magrolimab combinations across several solid tumor indications expected to be initiated in 1H 2021

Magrolimab has the potential to help address significant unmet medical need for MDS and AML patients




Oncology

An Important New Pillar of Growth


Key Oncology Portfolio Features

- Multiple new, **high-quality programs across all stages** of development and with diverse MOAs
- Approved transformational medicines provide benefit in **hematology and solid tumors**
- Enhanced oncology expertise** through acquisitions supplement Gilead's capability and improve ability to execute for growth



HIV Lenacapavir Could Be A Long-Acting Game-Changer


Lenacapavir Profile Highlights

- Potential **first-in-class** HIV capsid inhibitor
- **Highly potent** investigational agent, dosing as infrequently as **every 6 months**
- **Significantly reduced viral load** in proof-of-concept Phase 2/3 hTE¹ trial 
 - Anticipate FDA submission in 2H 2021
- **FDA Breakthrough Designation²**

6-month Dosing Unlocks Significant Potential

- Assuming equal safety, efficacy, and cost, more people prefer 6-month dosing option

Consumer Preference for Prevention Options³




¹ hTE = Heavily Treatment Experienced ² GS-6207 received breakthrough therapy designation from FDA as a potential therapy for heavily treatment-experienced (hTE) people living with multi-drug resistant HIV ³ Q2 2020 Gilead HIV prevention market research of at-risk individuals conducted across US (n=120), EU4 (n=120), UK (n=30), Canada (n=30) and Australia (n=30)



Accelerating Development of Lenacapavir in HIV Long-Acting Treatment and Prevention

Treatment

- NDA submission in hTE population anticipated in 2H 2021
- Phase 2 data in treatment naïve population to support virologically suppressed indication expected 2H 2021 
- Exploring internal and external partner agents for optimal combination regimens
 - Flexible dosing profile (oral and parenteral) supports possibility of **multiple long-acting options**
 - Potential combination regimen(s) expected to enter clinic in next 12-18 months

Prevention

- ***Monotherapy*** may be sufficient
- 6-month dosing could meet significant unmet need, materially increasing eligible population
- Phase 3 initiation for PrEP expected in 2021:
 - Cisgender men, transgender women, transgender men, and gender non-binary people who have sex with men 1H 2021
 - Adolescent girls and young women 2H 2021



Ongoing Remdesivir Clinical Development Program



**Reaching
additional
patient
populations and
care settings**

- Initiated Phase 3 study of **intravenous infusion of remdesivir in outpatient populations** at high risk for severe COVID-19 complications in Sep '20
- Completed Phase 1a study of an **inhaled remdesivir solution** in healthy volunteers and a Phase 1b study patients with early stage COVID-19
- Initiated Phase 2a study of an **inhaled remdesivir solution** in patients with early stage COVID-19 in Jan '21
- Other plans include **pediatric patients** (trial ongoing), **patients with renal failure and pregnant women**
- Completed **initial genomic analysis of the recently emerged variants** and anticipate remdesivir to be effective against these new variants
 - Testing of new variant isolates for susceptibility to remdesivir in progress



COVID-19 Insight: Timing estimates dependent upon the overall course of the pandemic.

Supporting numerous trials with remdesivir as **SOC** in combination with other agents to improve patient outcomes



Select 2021 Anticipated Milestones

Lenacapavir capsid inhibitor

Phase 3 initiation for PrEP

Hepcludex¹ (Bulevirtide)

Phase 3 data readout in HDV

Trodelvy (Sacituzumab govitecan-hziy)

MAA filing in 3L mTNBC

Trodelvy (Sacituzumab govitecan-hziy)

Anticipated sBLA full approval in 3L mTNBC

Trodelvy (Sacituzumab govitecan-hziy)

Anticipated sBLA approval in 3L mUC

Magrolimab

Phase 3 initiation in AML

Yescarta (Axi-cel)

Phase 3 data read out in 2L DLBCL

Yescarta (Axi-cel)

Anticipated MAA filing in iNHL

Yescarta (Axi-cel)

Anticipated sBLA approval in iNHL

Tecartus (Brexu-cel)

Anticipated sBLA/MAA submission in adult ALL

Domvanilimab (TIGIT)²

Phase 2 interim read out in NSCLC (ARC-7)

Ziritaxestat ATX inhibitor

Phase 3 futility analysis data read out in IPF



COVID-19 Impact: Some clinical trials continue to be impacted by the pandemic, which may result in delays in achieving milestones.



Viral Diseases



Inflammatory Diseases



Oncology



Regulatory approval or pivotal readout

Lenacapavir capsid inhibitor

Anticipated NDA submission in heavily treatment experienced population

Lenacapavir capsid inhibitor³

Phase 2 data read out for virologically suppressed population

Hepcludex¹ (Bulevirtide)

Anticipated BLA submission for HDV

Trodelvy (Sacituzumab govitecan-hziy)

Potential MAA approval in 3L mTNBC

Trodelvy (Sacituzumab govitecan-hziy)

Phase 3 data read out in HR+/HER2- mBC

Magrolimab

Phase 1b data read out in MDS

Magrolimab

Potential BLA/MAA submission for accelerated approval in MDS

Magrolimab + rituximab

Phase 1b/2 interim data read out in 3L+ DLBCL

Yescarta (Axi-cel)

Phase 2 data read out in 1L DLBCL

1H 2021

2H 2021

¹ From agreement to acquire MYR. Transaction has been announced but not yet closed. Closing of the transaction subject to regulatory clearances and other conditions. ² Optionable Partner Program. ³ Phase 2 study being conducted in treatment naïve patients to support virologically suppressed indication.

ALL – Acute lymphocytic leukemia, AML – Acute myeloid leukemia, Axi-cel - axicabtagene ciloleucel, Brexu-cel - brexucabtagene autoleucel, formerly KTE-X19, DLBCL – Diffuse large B cell lymphoma, HDV – Hepatitis delta virus, HR+/HER2- mBC – Hormone Receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, iNHL- indolent non-Hodgkin's lymphoma, MAA – Marketing authorization application, MDS – Myelodysplastic syndrome, mTNBC – Metastatic triple-negative breast cancer, mUC – Metastatic urothelial cancer, mNSCLC – Non small cell lung cancer, IPF – Idiopathic pulmonary fibrosis, PrEP – Pre-exposure prophylaxis, sBLA – Supplemental biologics license application.




Appendix



Non-GAAP Operating Income & Margin

in millions except percentages



Q4'20 operating income up 1% from Q3'20

- Increase due to higher operating income driven by Veklury
- Partially offset by higher R&D investments and other operating expenses

Q4'20 operating income up 62% from Q4'19

- Increase due to higher operating income driven by Veklury



GAAP to Non-GAAP Reconciliation of Outstanding Adjusted Debt and Adjusted EBITDA

in billions where applicable	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020
Total Debt, net	\$24.59	\$24.10	\$24.10	\$29.29	\$31.40
Debt Discounts, Premiums and Issuance Costs	0.16	0.15	0.15	0.21	0.20
Liability related to sale of future royalties ¹					(1.11)
Total Adjusted Debt¹	\$24.75	\$24.25	\$24.25	\$29.50	\$30.50

	Last Twelve Months Ended				
	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sep 30, 2020	Dec 31, 2020
Net Income attributable to Gilead	\$5.39	\$4.96	(\$0.26)	\$1.27	\$0.12
Add: Interest Expense ² & Other Income (expense), net	(0.87)	(0.36)	(0.39)	0.76	2.40
Add: Tax	(0.20)	(0.12)	(0.28)	0.52	1.58
Add: Depreciation	0.25	0.26	0.27	0.28	0.29
Add: Amortization	1.15	1.13	1.12	1.13	1.28
Add: Acquired in-process research and development expenses ³	5.05	5.02	9.38	6.59	5.86
Adjusted EBITDA^{4, 5}	\$10.76	\$10.90	\$9.85	\$10.54	\$11.52
Adjusted Debt to Adjusted EBITDA ratio⁵	~2.30x	~2.23x	~2.46x	~2.80x	~2.65x

¹ Represents a funding agreement with RPI Finance Trust that was assumed as part of our acquisition of Immunomedics under which Immunomedics received cash in exchange for perpetual, tiered royalty payments on worldwide sales of Trodelvy. This funding agreement is classified as debt. ² Total interest expense and amortization from all issued debt is expected to be approximately \$1 billion for full year 2021 that assumes that any early repayment of callable debt is done in December. ³ Beginning in Q3 2020, Adjusted EBITDA excludes all Acquired IPR&D expenses which comprise a separate line item on our Condensed Consolidated Statements of Operations. Prior to the change, Adjusted EBITDA excluded some, but not all charges aggregated within Acquired IPR&D expenses. Prior periods have been recast to reflect the change. Acquired IPR&D expenses reflect IPR&D impairments as well as the initial costs of externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects. ⁴ Represents the last twelve months of adjusted EBITDA. ⁵ Adjusted EBITDA and Adjusted Debt to Adjusted EBITDA ratio are non-GAAP performance measures used by our investors and analysts to assess the overall operating performance in the context of financial leverage.



GAAP to Non-GAAP Reconciliation of Full Year 2021 Guidance¹

in millions, except percentages and per share amounts

Provided on February 4, 2021

Projected product sales GAAP to non-GAAP reconciliation

GAAP projected product sales

\$23,700 - \$25,100

Less: Veklury sales

\$2,000 - \$3,000

Non-GAAP projected product sales excluding Veklury sales

\$21,700 - \$22,100

Projected product gross margin GAAP to non-GAAP reconciliation:

GAAP projected product gross margin

78% - 79%

Acquisition-related expenses

9%

Non-GAAP projected product gross margin

87% - 88%

Projected operating income GAAP to non-GAAP reconciliation:

GAAP projected operating income

\$9,300 - \$10,700

Acquisition-related and acquired IPR&D expenses

\$2,200

Non-GAAP projected operating income

\$11,500 - \$12,900

Projected effective tax rate GAAP to non-GAAP reconciliation:

GAAP projected effective tax rate

~23%

Less: Amortization of deferred tax assets and tax rate effects of adjustments noted above

2%

Non-GAAP projected effective tax rate

~21%

Projected diluted EPS GAAP to non-GAAP reconciliation:

GAAP projected diluted EPS

\$5.25 - \$5.95

Acquisition-related, acquired IPR&D expenses and amortization of deferred tax assets

\$1.50

Non-GAAP projected diluted EPS

\$6.75 - \$7.45



Inflammatory Disease Pipeline

			Pre-Clinical	Phase 1	Phase 2	Phase 3	Filed	Updates since Q3'20
Inflammatory Disease	Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis	▲	MAA Filed				MAA filed
	Filgotinib JAK-1 inhibitor (GS-6034)	Crohn's Disease						
	Filgotinib JAK-1 inhibitor (GS-6034)	Psoriatic arthritis	▲					Removed from pipeline
	Filgotinib JAK-1 inhibitor (GS-6034)	Ankylosing spondylitis	▲					Removed from pipeline
	Filgotinib JAK-1 inhibitor (GS-6034)	Uveitis	▲					Removed from pipeline
	TPL2 inhibitor (GS-4875)	Ulcerative colitis	▲					Removed from pipeline
	TPL2 inhibitor (GS-5290)	Inflammatory Bowel Disease	★					New
	IRAK4 inhibitor (GS-5718)	Inflammatory Bowel Disease						
	IRAK4 inhibitor (GS-5718)	Lupus	★					New
	Tirabrutintib BTK inhibitor (GS-4059)	CSU	★					New
	α4β7 inhibitor (GS-1427)	Inflammatory Bowel Disease						
	Small molecule inhibitor (neutrophil target)	Inflammatory Diseases						
	Small molecule inhibitor (innate immunity target)	Inflammatory Diseases						
Fibrotic Disease	Cilofexor FXR agonist (GS-9674)	PSC						
	Ziritaxestat ATX inhibitor (GLPG-1690)	IPF						
	Cilofexor / firsocostat combination	NASH						
	Selonsertib ASK1 inhibitor (GS-4997)	DKD						
	Ziritaxestat ATX inhibitor (GLPG-1690)	Systemic Sclerosis	▲					Removed from pipeline
Options	Galapagos	Inflammatory and Fibrosis Diseases		8 clinical stage programs				
	Galapagos	Inflammatory and Fibrosis Diseases		Multiple pre-clinical stage programs				

★ New listing since Q3'20 ▲ Change since Q3'20



Oncology Cell Therapy Pipeline

		Pre-Clinical	Phase 1	Phase 2	Phase 3	Filed	Updates since Q3'20
Cell Therapy	Tecartus™ (Brexu-cel) ¹	MCL	▲	MAA and BLA Approved			MAA approved
	Axi-cel	iNHL	●	sBLA Filed			
	Yescarta® (Axi-cel)	2L DLBCL					
	Yescarta® (Axi-cel)	1L DLBCL					
	Brexu-cel	Adult ALL	●	Pivotal			
	Brexu-cel	Pediatric ALL	●	Pivotal			
	Yescarta® (Axi-cel) ²	3L DLBCL (+rituximab)					
	Yescarta® (Axi-cel) ³	3L DLBCL (+lenzilumab)					
	Yescarta® (Axi-cel) ⁴	3L DLBCL (+utomilumab)					
	KITE-718 (MAGE-A3/A6) ⁵	Solid Tumor					
	KITE-439 (HPV-16 E7) ⁵	Solid Tumor					
	Brexu-cel	CLL					
	KITE-037 (Allo-HD CD19) ⁶	R/R DLBCL					
	KITE-222 (CLL-1)	AML					
KITE-363 (Dual targeting)	R/R DLBCL						

★ New listing since Q3'20 ▲ Change since Q3'20
● Breakthrough Therapy Designation

¹ Conditional approvals. ² Clinical collaboration with Genentech. ³ Clinical collaboration with Humanigen. ⁴ Clinical collaboration with Pfizer. ⁵ Collaboration with NIH. ⁶ Partnership with Sangamo.

ALL - Acute lymphocytic leukemia. AML - Acute myeloid leukemia. Axi-cel - Axicabtagene Ciloleucl. Brexu-cel - Brexucabtagene autoleucl. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B cell lymphoma. iNHL - indolent non-Hodgkin's lymphoma. MCL - Mantle cell lymphoma. R/R - relapsed / refractory. Pipeline shown above as of end of Q4'20.



Oncology Non-Cell Therapy Pipeline

			Pre-Clinical	Phase 1	Phase 2	Phase 3	Filed	Updates since Q3'20	
Non-Cell Therapy	Trodelvy™ Sacituzumab govitecan-hziy ¹	mTNBC (3L)	● ▲	[Progress bar]				sBLA	sBLA filed for full approval
	Sacituzumab govitecan-hziy (GS-0132)	Urothelial (3L+)	● ▲	[Progress bar]				sBLA for AA	sBLA filed for accelerated approval
	Magrolimab anti-CD47 (GS-4721) ²	MDS	P ●	[Progress bar]					
	Sacituzumab govitecan-hziy (GS-0132)	HR+/HER2-mBC (3L+)		[Progress bar]					
	Sacituzumab govitecan-hziy (GS-0132)	Basket (incl. NSCLC)		[Progress bar]					
	Sacituzumab govitecan-hziy (GS-0132) + CPI	mTNBC (1L), mUC, mNSCLC		[Progress bar]				Phase 1b/2	
	Magrolimab anti-CD47 (GS-4721)	AML		[Progress bar]				Phase 1b/2	
	Zimberelimab PD1 (GS-0122) ³	NSCLC		[Progress bar]					
	Magrolimab anti-CD47 (GS-4721)	DLBCL		[Progress bar]				Phase 1b/2	
	Sacituzumab govitecan-hziy (GS-0132) + PARPi	mTNBC, mUC, Ovarian	▲	[Progress bar]				Phase 1b/2	P1 → P1b/2
	Oral PD-L1 small molecule inhibitor (GS-4224)	NSCLC		[Progress bar]					
	Anti-CD73/TGFβ Trap (GS-1423)	ONC	▲	[Progress bar]					Removed from pipeline
	Magrolimab anti-CD47 (GS-4721)	Solid Tumors		[Progress bar]					
	Flt3R agonist (GS-3583)	ONC		[Progress bar]					
	Anti-c-KIT (GS-0174)	TCR	▲	[Progress bar]				Phase 1a	PC → P1
	Anti-SIRP-a (GS-0189)	ONC	▲	[Progress bar]				Phase 1a	PC → P1
	MCL1 inhibitor (GS-9716)	ONC		[Progress bar]					
	TME target	ONC		[Progress bar]					
	T cell activator	ONC		[Progress bar]					
	CCR8 (GS-1811)	Solid Tumors		[Progress bar]					
Options	Arcus	ONC		3 clinical stage programs					
	Agenus	Solid Tumors		2 clinical stage programs					
	Tizona	Advanced Cancers		1 clinical stage program					
	Pionyr	Solid Tumors		2 clinical stage programs					

★ New listing since Q3'20 ▲ Change since Q3'20
 ● Breakthrough Therapy Designation P PRIME Designation

¹ Accelerated FDA approval granted. ² Breakthrough and PRIME designation. ³ Non-Gilead sponsored trial(s) ongoing.
 AML – Acute myeloid leukemia. CPI – Checkpoint inhibitor. DLBCL – Diffuse large B cell lymphoma. HR+/HER2- mBC – Hormone Receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. MDS – Myelodysplastic syndrome.
 mTNBC – Metastatic triple-negative breast cancer. mUC – metastatic urothelial cancer. mNSCLC – metastatic non-small cell lung cancer. NSCLC – Non small cell lung cancer. PARPi – PARP inhibitor. TCR – Transplant conditioning regimen. TME – Tumor microenvironment.
 Pipeline shown above as of end of Q4'20.





THANK YOU

CONTACT US

investor_relations@gilead.com
investors.gilead.com